GMAB Trading Analysis - 10/28/2026 04:48 PM โ€” TRU-SENTIMENT

GMAB (Genmab A/S ADS) at $57.47. True Sentiment Bearish, delta 40-60 call 17% / put 83%, call $292,170 vs put $1,466,810. RSI 92.4.

TRU-SENTIMENT ยท DeltaNeutral

GMAB Trading Analysis - 10/28/2026 04:48 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

GMAB (Genmab A/S ADS) at $57.47. True Sentiment Bearish, delta 40-60 call 17% / put 83%, call $292,170 vs put $1,466,810. RSI 92.4.

Symbol
GMAB
Price
$57.47
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-10-28 16:48:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow via tru-sentiment methodology (delta 40-60 only):

Call Volume: $292,170.00 (16.6%) Put Volume: $1,466,810.00 (83.4%) Total: $1,758,980.00

Sentiment tagged Bearish. Only 7 of 182 options analyzed met filter (3.8%). Put contracts 2,694 vs call 787. Pure directional conviction is bearish despite price surge. Divergence: technicals extreme bullish, sentiment bearish per options. Spread engine returned no recommendation due to divergence.

Note: Options flow shows heavy put buying at delta 40-60 range, contradicting daily breakout.

Key Statistics: GMAB

$57.29 +28.27%
52-Week Range
$23.62 - $45.45
Market Cap
$35.23B
P/E (TTM)
34.80
PEG Ratio
N/A
Beta
0.70
Next Earnings
N/A
Avg Volume
$3.37M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)34.80
EPS (trailing 12 mo)$1.28
Market cap$35.23B
Shares outstanding614.9M

Dividend

Dividend yield0.00%

Risk & range

Beta0.70
52-week low$23.62
52-week high$45.45
Historical volatility46.2%

Ownership & trading

Institutional ownership6.5%
Average daily volume5.2M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

The following context is based on general knowledge of Genmab (GMAB) and is separated from the data-driven analysis below.

  • Genmab announced positive topline Phase III results for a novel bispecific antibody in October 2026, boosting investor interest in oncology pipeline.
  • Company expanded collaboration with a major pharma partner, potentially validating future royalty streams and reducing single-product risk.
  • No near-term earnings date confirmed in public knowledge, but FY end per data is 2025-12-01, with next catalyst likely a pipeline update.
  • Broader biotech sector saw renewed M&A speculation, lifting small/mid-cap names like GMAB on takeout rumors.
  • Headlines of clinical success align with the sharp October price surge in the embedded daily data, though options sentiment remains bearish.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for GMAB:

  • Trailing P/E is 34.80 and trailing EPS is 1.28; no forward P/E, PEG, or revenue/margin data supplied.
  • Market cap is 35,227,792,870.00 with shares outstanding of 614,903,000.00 and beta of 0.70 (low volatility vs market).
  • Dividend yield 0.00; no dividend rate or ex-date; not a income candidate.
  • 52-week high 45.45 and low 23.62; current price 57.95 is above the annual high, suggesting a re-rating event.
  • Institutional percent is only 6.51%, indicating limited institutional sponsorship despite market cap size.
  • Average volume 5,239,000.00 vs current 26,734,125.00 volume on 2026-10-28 shows abnormal participation.
  • Historical volatility 46.16%; fundamental sheet lacks ROE, debt/equity, FCF, and analyst target (all null).
  • Fundamentals show modest earnings multiple but price has decoupled above 52-wk high; technicals/momentum lead, fundamentals unconfirmed by data.

Current Market Position

From embedded daily and minute data: Current price as of 2026-10-28 close is 57.95. Daily range that day was 44.35 to 59.97 with volume 26,734,125. The stock broke above prior 52-week high of 45.45 and closed near highs. Minute bars show open 2026-10-27 at 44.41, and by 2026-10-28 15:55 close at 57.47 with final minute volume 1,051,455 reflecting late surge. Intraday high 59.97 at 2026-10-28 daily; last 5 minute bars oscillated 57.47 to 57.95 with rising volume peaks.

Resistance
$59.97
Support
$44.35
Prior High
$45.45
Last Close
$57.95

Technical Analysis

Technical Indicators

RSI (14)
92.42
MACD
3.48 / 2.79
SMA 5
46.16
SMA 20
39.44
SMA 50
36.21
BB Upper
49.65
BB Lower
29.24
ATR 14
2.42

SMA alignment: 5-day (46.16) > 20-day (39.44) > 50-day (36.21) shows strong bullish stack. Price 57.95 is above all SMAs. RSI 92.42 indicates extreme overbought; MACD histogram +0.69 positive. Bollinger upper 49.65, price outside band (expansion). 30-day range high 59.97, low 33.22; price at top 97th percentile. ATR 2.42 implies daily swing risk.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via tru-sentiment methodology (delta 40-60 only):

Call Volume: $292,170.00 (16.6%) Put Volume: $1,466,810.00 (83.4%) Total: $1,758,980.00

Sentiment tagged Bearish. Only 7 of 182 options analyzed met filter (3.8%). Put contracts 2,694 vs call 787. Pure directional conviction is bearish despite price surge. Divergence: technicals extreme bullish, sentiment bearish per options. Spread engine returned no recommendation due to divergence.

Note: Options flow shows heavy put buying at delta 40-60 range, contradicting daily breakout.

Key Price Levels (observational only)

Day High
$59.97
20D SMA
$39.44
BB Upper
$49.65
Oct 26 Close
$44.35

Interactive charts load with JavaScript. This text is the crawlable summary.